A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features.
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Gemcitabine (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 22 Mar 2013 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University: ECOG1808).
- 22 Nov 2012 New source identified and integrated (Mayo Clinic; NCT01164228).
- 11 Jul 2012 Planned end date changed from 1 Sep 2011 to 1 Jun 2021 as reported by ClinicalTrials.gov.